Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Removal of Low-Radioactivity Sentinel Lymph Nodes Recommended

By HospiMedica International staff writers
Posted on 05 Feb 2009
A new study suggests that multiple lymphatic channels may exist, draining into more than one sentinel lymph node (SNL), and recommends that SLNs with low radioactivity should also be removed to ensure complete resection.

Researchers from the University of California San Francisco (USA) sought to validate the "10% rule” hypothesis, which states that while the hottest SLN has the highest likelihood of harboring tumor cells, all nodes with more than 10% of the ex vivo radioactive count of the hottest SLN should be removed. More...
The researchers found that among 332 primary breast cancer patients who underwent sentinel lymphadenectomy, the radioactivity of the positive nodes apart from the hottest node ranged between 0.8% and 90% of the counts of the hottest lymph node, but only 6.5% of radioactive nodes had less than 10% of the radioactivity of the hottest lymph node. Only nine lymph nodes (15%) with radioactive counts less than 10% of the hottest lymph node were found to harbor tumor cells, with the lowest radioactivity of a node positive for cancer reaching 4.2% of the radioactivity of the hottest node. The researchers found that if only the hottest node was removed, the false-negative rate was 14.1% and the accuracy 96.7%; but if the 10% rule was applied, the false-negative rate dropped to 6.4% and accuracy increased to 98.5%. The study was published in the December 2008 issue of the Journal of the American College of Surgeons.

"These findings indicate that there is more than one sentinel lymph node, suggesting that more than one lymphatic channel can lead the cancer cells to one or more sentinel lymph nodes,” said lead author Stanley Leong. M.D. "In order to reduce the false-negative rate, the surgeon needs to take out not only the hottest lymph node but also additional ones, as low as to, [or] at least, 10% of the hottest lymph node.”

Prior to sentinel lymph node biopsy, the surgeon injects a small dose of a low-level radioactive tracer called technetium-99 into the breast in the region of the patient's tumor. A blue dye is also injected to help visually track the location of the sentinel node during surgery. Depending on the protocol followed, the surgeon usually waits between 45 minutes to 8 hours after injection before bringing the patient to the operating room for the biopsy. Once the technetium-99 tracer and dye have reached the nodes, the surgeon scans the area with a hand-held Geiger gamma ray counter attached to a probe used to trace the SNLs. When the radioactive agent is found, the gamma ray counter will emit an audible tone, revealing the exact location of the sentinel node(s). The blue dye provides additional visual confirmation of the sentinel node's location during surgical removal.

Related Links:

University of California San Francisco




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.